CONMED
CNMD
173 hedge funds and large institutions have $1.73B invested in CONMED in 2018 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 59 increasing their positions, 58 reducing their positions, and 16 closing their positions.
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
22% more capital invested
Capital invested by funds: $1.42B → $1.73B (+$307M)
8% more funds holding
Funds holding: 160 → 173 (+13)
2% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 58
6% less call options, than puts
Call options by funds: $767K | Put options by funds: $817K
2.24% less ownership
Funds ownership: 99.72% → 97.47% (-2.2%)
Top Buyers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$19.9M |
| 2 |
BlackRock
New York
|
+$16.5M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
+$6.32M |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$6.14M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.43M |
Top Sellers
| 1 |
SCM
Scopia Capital Management
New York
|
-$35.8M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$24.8M |
| 3 |
CRM
Cramer Rosenthal McGlynn
Stamford,
Connecticut
|
-$13.4M |
| 4 |
Goldman Sachs
New York
|
-$10.8M |
| 5 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$9.28M |
CNMD Hedge Fund Activity: Q1 2018 in Review
173 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q1 2018, worth a combined $1.73B — up 22% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CNMD positions and 16 closed out — a net gain of 14 holders — while 59 added to existing stakes and 58 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $19.9M. The largest seller was Scopia Capital Management, cutting an estimated $35.8M.
- 173 institutional investors held CONMED (CNMD) as of Q1 2018, up from 160 in Q4 2017.
- Funds reported $1.73B of CONMED stock for Q1 2018, up 22% quarter-over-quarter.
- 30 funds opened new CONMED positions in Q1 2018 and 16 closed out, a net change of +14 holders.
- The largest CONMED buyer in Q1 2018 was Capital Research Global Investors, an estimated $19.9M added.
- The largest CONMED seller in Q1 2018 was Scopia Capital Management, an estimated $35.8M sold.
Based on aggregated 13F filings for Q1 2018.